Courtade-Saïdi M, Aziza J, d'Aure D, Bérard E, Evrard S, Basset C, Lacoste-Collin L
Department of Pathology and Cytology, University Cancer Institute Toulouse Oncopole, Toulouse Universitary Hospital, Toulouse, France.
Department of Epidemiology, Health Economics and Public Health, UMR-1027 INSERM Toulouse University School of Medicine, Toulouse University Hospital, Toulouse, France.
Cytopathology. 2016 Dec;27(6):456-464. doi: 10.1111/cyt.12332. Epub 2016 Mar 8.
The presence of atypical cells in urine cytology is unsatisfactory for both cytologists and clinicians. The objective of this study was to test whether p53 and Ki-67 immunostaining could improve urothelial carcinoma (UC) detection on urinary cytology.
A total of 196 urine samples were analysed, 142 from the bladder, 41 from the upper tract and 13 from ileal bladder replacement. Cytology results were expressed as normal (N) (n = 81), atypia cannot exclude low-grade UC (ALG) (n = 25), suspicious for high-grade UC (SHG) (n = 39) and high-grade UC (HG) (n = 51). Actual diagnoses were confirmed by histopathological analysis, cystoscopic examination or follow-up for at least 1 year. Immunocytochemistry performed on CytoSpin slides allowed the determination of the percentage of positive cells with p53 and Ki-67.
The median percentage values [first to third quartile] of p53 and Ki-67 were 0 [0-5] and 0 [0-1] for N cytology, 5 [0-40] and 2 [1-10] for ALG, 10 [0-30] and 6 [3-25] for SHG, and 30 [10-80] and 20 [10-30] for HG, respectively. Statistically higher values were observed for both tests (P < 0.001) in positive cytologies (ALG, SHG and HG). The optimal cut-offs were 5% for p53 and 3% for Ki-67. The sensitivity and specificity for the detection of all UC were 86.4% and 76.7% for cytology alone, 81.3% and 93.2% for cytology and p53, 75.7% and 88% for cytology and Ki-67, and 68.9% and 97.5% for cytology, p53 and Ki-67, respectively.
Using p53 and/or Ki-67 in addition to cytology increases the specificity without penalising the sensitivity.
尿细胞学检查中出现非典型细胞对细胞病理学家和临床医生来说都不尽人意。本研究的目的是测试p53和Ki-67免疫染色是否能提高尿细胞学检查对尿路上皮癌(UC)的检测能力。
共分析了196份尿液样本,其中142份来自膀胱,41份来自上尿路,13份来自回肠膀胱替代术。细胞学结果分为正常(N)(n = 81)、非典型细胞不能排除低级别UC(ALG)(n = 25)、可疑高级别UC(SHG)(n = 39)和高级别UC(HG)(n = 51)。实际诊断通过组织病理学分析、膀胱镜检查或至少1年的随访得以证实。对经细胞离心涂片机制备的玻片进行免疫细胞化学检测,以确定p53和Ki-67阳性细胞的百分比。
N细胞学中p53和Ki-67的中位数百分比值[第一四分位数至第三四分位数]分别为0[0 - 5]和0[0 - 1],ALG为5[0 - 40]和2[1 - 10],SHG为10[0 - 30]和6[3 - 25],HG为30[10 - 80]和20[10 - 30]。在阳性细胞学结果(ALG、SHG和HG)中,两项检测的数值在统计学上均更高(P < 0.001)。p53的最佳临界值为5%,Ki-67为3%。单独细胞学检查对所有UC检测的敏感性和特异性分别为86.4%和76.7%,细胞学与p53联合检测为81.3%和93.2%,细胞学与Ki-67联合检测为75.7%和88%,细胞学、p53和Ki-67联合检测为68.9%和97.5%。
除细胞学检查外,使用p53和/或Ki-67可提高特异性而不影响敏感性。